Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3 Colorectal Neoplasms 3 Colonic Neoplasms 3 Uterine Cervical Dysplasia 1 Stomatitis 1 Rectal Neoplasms 1 Pain 1 Neurofibromatosis 1 1 Lung Neoplasms 1 Castration Sensitive Prostate Cancer 1 Breast Neoplasms 1 Advanced Cancers 1

Interventions

pazopanib 3 Erlotinib Hydrochloride 3 Cetuximab 3 Vorinostat 2 Oxaliplatin 2 Bevacizumab 2 Azacitidine 2 satraplatin 1 ixazomib 1 X-Rays 1 Valproic Acid 1 Trastuzumab 1 Sorafenib 1 Platinum 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lenalidomide 1 Lapatinib 1 LY 2275796 1 Injections, Subcutaneous 1 Fluorouracil 1 Everolimus 1 Curcumin 1 Crizotinib 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 AH 111585 1 10-propargyl-10-deazaaminopterin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Cancers × Curcumin × Clear all

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡